and this "background" was subtracted from subsequent samples.
The sensitivity of the assay was 500 pg/mL.
Data analysis.
The half-life which values were different.
RESULTS

Pharmacokinetics ofG-CSF administered
IV. the third patient showed a steady decline from the peak. At 24 hours, serum levels were < 10% of the peak level. (Fig 3A) , and another group received melphalan on day I and G-CSF on days 8 through I 8 (Fig 3B) . In these Although data are insufficient to be conclusive, the data in Table  I suggest that the t'/2 was reduced when neutrophil counts were elevated on the later days of treat- 
